{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:46:49Z","timestamp":1765547209871},"reference-count":81,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,19]]},"DOI":"10.7759\/cureus.56454","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T11:29:51Z","timestamp":1710847791000},"source":"Crossref","is-referenced-by-count":1,"title":["Typhoid Conjugate Vaccine: A Boon for Endemic Regions"],"prefix":"10.7759","author":[{"given":"Nitesh","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishant","family":".","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra","family":"H.S.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trayambak","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy191","article-title":"Designing comprehensive public health surveillance for enteric fever in endemic countries: importance of including different healthcare facilities","volume":"218","author":"Saha S","year":"2018","unstructured":"Saha S, Islam M, Saha S, et al.. Designing comprehensive public health surveillance for enteric fever in endemic countries: importance of including different healthcare facilities. J Infect Dis. 2018, 218:S227-31. 10.1093\/infdis\/jiy191","journal-title":"J Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0586","article-title":"Rotavirus vaccine will improve child survival by more than just preventing diarrhea: evidence from Bangladesh","volume":"98","author":"Saha S","year":"2018","unstructured":"Saha S, Santosham M, Hussain M, Black RE, Saha SK. Rotavirus vaccine will improve child survival by more than just preventing diarrhea: evidence from Bangladesh. Am J Trop Med Hyg. 2018, 98:360-3. 10.4269\/ajtmh.17-0586","journal-title":"Am J Trop Med Hyg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005376","article-title":"The burden of typhoid fever in low- and middle-income countries: a meta-regression approach","volume":"11","author":"Antill\u00f3n M","year":"2017","unstructured":"Antill\u00f3n M, Warren JL, Crawford FW, et al.. The burden of typhoid fever in low- and middle-income countries: a meta-regression approach. PLoS Negl Trop Dis. 2017, 11:e0005376. 10.1371\/journal.pntd.0005376","journal-title":"PLoS Negl Trop Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30350-5","article-title":"Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance","volume":"19","author":"Andrews JR","year":"2019","unstructured":"Andrews JR, Baker S, Marks F, et al.. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. Lancet Infect Dis. 2019, 19:26-30. 10.1016\/S1473-3099(18)30350-5","journal-title":"Lancet Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale V","year":"2014","unstructured":"Mogasale V, Maskery B, Ochiai RL, et al.. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014, 2:570-80. 10.1016\/S2214-109X(14)70301-8","journal-title":"Lancet Glob Health"},{"key":"ref6","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019. (2020). Accessed. January 19, 2024: https:\/\/www.healthdata.org\/research-analysis\/gbd."},{"key":"ref7","unstructured":"Typhoid and other invasive salmonellosis. (2018). Accessed. February 10, 2024: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/vpd_surveillance\/vpd-surveillance-standards-publication\/wh...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy884","article-title":"Overview of the typhoid conjugate vaccine pipeline: current status and future plans","volume":"68","author":"Sahastrabuddhe S","year":"2019","unstructured":"Sahastrabuddhe S, Saluja T. Overview of the typhoid conjugate vaccine pipeline: current status and future plans. Clin Infect Dis. 2019, 68:S22-6. 10.1093\/cid\/ciy884","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7207a2","article-title":"Typhoid fever surveillance, incidence estimates, and progress toward typhoid conjugate vaccine introduction - worldwide, 2018-2022","volume":"72","author":"Hancuh M","year":"2023","unstructured":"Hancuh M, Walldorf J, Minta AA, et al.. Typhoid fever surveillance, incidence estimates, and progress toward typhoid conjugate vaccine introduction - worldwide, 2018-2022. MMWR Morb Mortal Wkly Rep. 2023, 72:171-6. 10.15585\/mmwr.mm7207a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref10","unstructured":"Weekly Epidemiological Record (WER). (2018). Accessed. January 19, 2024: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/272272\/WER9313.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy846","article-title":"Progress in typhoid fever epidemiology","volume":"68","author":"Crump JA","year":"2019","unstructured":"Crump JA. Progress in typhoid fever epidemiology. Clin Infect Dis. 2019, 68:S4-9. 10.1093\/cid\/ciy846","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020201","article-title":"Typhoid fever","volume":"347","author":"Parry CM","year":"2002","unstructured":"Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002, 347:1770-82. 10.1056\/NEJMra020201","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67181-4","article-title":"Typhoid and paratyphoid fever","volume":"366","author":"Bhan MK","year":"2005","unstructured":"Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005, 366:749-62. 10.1016\/S0140-6736(05)67181-4","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008048","article-title":"Changes in historical typhoid transmission across 16 U.S. cities, 1889-1931: Quantifying the impact of investments in water and sewer infrastructures","volume":"14","author":"Phillips MT","year":"2020","unstructured":"Phillips MT, Owers KA, Grenfell BT, Pitzer VE. Changes in historical typhoid transmission across 16 U.S. cities, 1889-1931: Quantifying the impact of investments in water and sewer infrastructures. PLoS Negl Trop Dis. 2020, 14:e0008048. 10.1371\/journal.pntd.0008048","journal-title":"PLoS Negl Trop Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.10.030","article-title":"Complications and mortality of typhoid fever: a global systematic review and meta-analysis","volume":"81","author":"Marchello CS","year":"2020","unstructured":"Marchello CS, Birkhold M, Crump JA. Complications and mortality of typhoid fever: a global systematic review and meta-analysis. J Infect. 2020, 81:902-10. 10.1016\/j.jinf.2020.10.030","journal-title":"J Infect"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.1967","article-title":"Epidemiology, clinical presentation, and patterns of drug resistance of Salmonella Typhi in Karachi, Pakistan","volume":"6","author":"Khan MI","year":"2012","unstructured":"Khan MI, Soofi SB, Ochiai RL, et al.. Epidemiology, clinical presentation, and patterns of drug resistance of Salmonella Typhi in Karachi, Pakistan. J Infect Dev Ctries. 2012, 6:704-14. 10.3855\/jidc.1967","journal-title":"J Infect Dev Ctries"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-micro-091313-103739","article-title":"Salmonella enterica serovar Typhi and the pathogenesis of typhoid fever","volume":"68","author":"Dougan G","year":"2014","unstructured":"Dougan G, Baker S. Salmonella enterica serovar Typhi and the pathogenesis of typhoid fever. Annu Rev Microbiol. 2014, 68:317-36. 10.1146\/annurev-micro-091313-103739","journal-title":"Annu Rev Microbiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30050-3","article-title":"A new vaccine for typhoid control","volume":"391","year":"2018","unstructured":"A new vaccine for typhoid control. Lancet. 2018, 391.96. 10.1016\/S0140-6736(18)30050-3","journal-title":"Lancet"},{"key":"ref19","article-title":"Vaccination against typhoid fever: present status","volume":"72","author":"Ivanoff B","year":"1994","unstructured":"Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull World Health Organ. 1994, 72:957-71.","journal-title":"Bull World Health Organ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00231-5","article-title":"Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine","volume":"2","author":"Levine MM","year":"1999","unstructured":"Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine. 1999, 2:22-7. 10.1016\/S0264-410X(99)00231-5","journal-title":"Vaccine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy962","article-title":"Evidence to Action: The 10th International Conference on Typhoid and Other Invasive Salmonelloses","volume":"68","author":"Lindsay S","year":"2019","unstructured":"Lindsay S, Garrett D, Steele D. Evidence to Action: The 10th International Conference on Typhoid and Other Invasive Salmonelloses. Clin Infect Dis. 2019, 68:S1-3. 10.1093\/cid\/ciy962","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001261.pub2","article-title":"Vaccines for preventing typhoid fever","volume":"2007","author":"Fraser A","year":"2007","unstructured":"Fraser A, Goldberg E, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2007, 2007:CD001261. 10.1002\/14651858.CD001261.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/jtm.12171","article-title":"Vaccine-preventable travel health risks: what is the evidence--what are the gaps?","volume":"22","author":"Steffen R","year":"2015","unstructured":"Steffen R, Behrens RH, Hill DR, Greenaway C, Leder K. Vaccine-preventable travel health risks: what is the evidence--what are the gaps?. J Travel Med. 2015, 22:1-12. 10.1111\/jtm.12171","journal-title":"J Travel Med"},{"key":"ref24","unstructured":"Background paper to SAGE on typhoid vaccine policy recommendations. (2017). Accessed. January 19, 2024: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/position_paper_documents\/typhoid\/1-typhoid-sage-background...."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_1890_17","article-title":"The need & the issues related to new-generation typhoid conjugate vaccines in India","volume":"151","author":"Vashishtha VM","year":"2020","unstructured":"Vashishtha VM, Kalra A. The need &amp; the issues related to new-generation typhoid conjugate vaccines in India. Indian J Med Res. 2020, 151:22-34. 10.4103\/ijmr.IJMR_1890_17","journal-title":"Indian J Med Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807521","article-title":"A cluster-randomized effectiveness trial of Vi typhoid vaccine in India","volume":"361","author":"Sur D","year":"2009","unstructured":"Sur D, Ochiai RL, Bhattacharya SK, et al.. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med. 2009, 361:335-44. 10.1056\/NEJMoa0807521","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.015","article-title":"Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan","volume":"30","author":"Khan MI","year":"2012","unstructured":"Khan MI, Soofi SB, Ochiai RL, et al.. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine. 2012, 30:5389-95. 10.1016\/j.vaccine.2012.06.015","journal-title":"Vaccine"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin S","year":"2014","unstructured":"Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. 2014, 111:12283-7. 10.1073\/pnas.1400472111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ976","article-title":"Challenges and opportunities for typhoid fever control: a call for coordinated action","volume":"62 Suppl 1","author":"Steele AD","year":"2016","unstructured":"Steele AD, Hay Burgess DC, Diaz Z, Carey ME, Zaidi AK. Challenges and opportunities for typhoid fever control: a call for coordinated action. Clin Infect Dis. 2016, 62 Suppl 1:S4-8. 10.1093\/cid\/civ976","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin C","year":"2017","unstructured":"Jin C, Gibani MM, Moore M, et al.. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017, 390:2472-80. 10.1016\/S0140-6736(17)32149-9","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1128\/iai.57.12.3823-3827.1989","article-title":"Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi","volume":"57","author":"Szu SC","year":"1989","unstructured":"Szu SC, Li XR, Schneerson R, Vickers JH, Bryla D, Robbins JB. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect Immun. 1989, 57:3823-7. 10.1128\/iai.57.12.3823-3827.1989","journal-title":"Infect Immun"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2003.01292.x","article-title":"Mucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?","volume":"58","author":"Jakobsen H","year":"2003","unstructured":"Jakobsen H, Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?. Scand J Immunol. 2003, 58:119-28. 10.1046\/j.1365-3083.2003.01292.x","journal-title":"Scand J Immunol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.166.5.1510","article-title":"Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals","volume":"166","author":"Szu SC","year":"1987","unstructured":"Szu SC, Stone AL, Robbins JD, Schneerson R, Robbins JB. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med. 1987, 166:1510-24. 10.1084\/jem.166.5.1510","journal-title":"J Exp Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new Vi-CRM\u2081\u2089\u2087 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults","volume":"6","author":"van Damme P","year":"2011","unstructured":"van Damme P, Kafeja F, Anemona A, et al.. Safety, immunogenicity and dose ranging of a new Vi-CRM\u2081\u2089\u2087 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One. 2011, 6:e25398. 10.1371\/journal.pone.0025398","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad132","article-title":"Programmatic effectiveness of a pediatric typhoid conjugate vaccine campaign in Navi Mumbai, India","volume":"77","author":"Hoffman SA","year":"2023","unstructured":"Hoffman SA, LeBoa C, Date K, et al.. Programmatic effectiveness of a pediatric typhoid conjugate vaccine campaign in Navi Mumbai, India. Clin Infect Dis. 2023, 77:138-44. 10.1093\/cid\/ciad132","journal-title":"Clin Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.12.007","article-title":"A phase II\/III, multicenter, observer-blinded, randomized, non-inferiority and safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV\u00ae in healthy 6 Months-45 years aged participants","volume":"41","author":"Ok Baik Y","year":"2023","unstructured":"Ok Baik Y, Lee Y, Lee C, et al.. A phase II\/III, multicenter, observer-blinded, randomized, non-inferiority and safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV\u00ae in healthy 6 Months-45 years aged participants. Vaccine. 2023, 41:1753-9. 10.1016\/j.vaccine.2022.12.007","journal-title":"Vaccine"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2203634","article-title":"A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal","volume":"19","author":"Chaudhary S","year":"2023","unstructured":"Chaudhary S, Shah GS, Bhatta NK, et al.. A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal. Hum Vaccin Immunother. 2023, 19:2203634. 10.1080\/21645515.2023.2203634","journal-title":"Hum Vaccin Immunother"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac289","article-title":"Prevention of typhoid by vi conjugate vaccine and achievable improvements in household water, sanitation, and hygiene: evidence from a cluster-randomized trial in Dhaka, Bangladesh","volume":"75","author":"Tadesse BT","year":"2022","unstructured":"Tadesse BT, Khanam F, Ahmmed F, et al.. Prevention of typhoid by vi conjugate vaccine and achievable improvements in household water, sanitation, and hygiene: evidence from a cluster-randomized trial in Dhaka, Bangladesh. Clin Infect Dis. 2022, 75:1681-7. 10.1093\/cid\/ciac289","journal-title":"Clin Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-022-2520-7","article-title":"Long-term persistence of immunogenicity after primary vaccination and response to booster vaccination with typhoid conjugate vaccine: results of a phase IV extension study","volume":"59","author":"Kandulna AK","year":"2022","unstructured":"Kandulna AK, Uttam KG, Sharma S, et al.. Long-term persistence of immunogenicity after primary vaccination and response to booster vaccination with typhoid conjugate vaccine: results of a phase IV extension study. Indian Pediatr. 2022, 59:388-92. 10.1007\/s13312-022-2520-7","journal-title":"Indian Pediatr"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.08.034","article-title":"Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15\u00a0months old Nepalese infants","volume":"40","author":"Saluja T","year":"2022","unstructured":"Saluja T, Rai GK, Chaudhary S, et al.. Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15\u00a0months old Nepalese infants. Vaccine. 2022, 40:5828-34. 10.1016\/j.vaccine.2022.08.034","journal-title":"Vaccine"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2043103","article-title":"A multicenter, single-blind, randomized, phase-2\/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM(197) conjugate typhoid vaccine (TyphiBEV(TM)) in healthy infants, children, and adults in comparison with a licensed comparator","volume":"18","author":"Thuluva S","year":"2022","unstructured":"Thuluva S, Paradkar V, Matur R, Turaga K, Gv SR. A multicenter, single-blind, randomized, phase-2\/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM(197) conjugate typhoid vaccine (TyphiBEV(TM)) in healthy infants, children, and adults in comparison with a licensed comparator. Hum Vaccin Immunother. 2022, 18:2043103. 10.1080\/21645515.2022.2043103","journal-title":"Hum Vaccin Immunother"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00275-3","article-title":"Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial","volume":"10","author":"Nampota-Nkomba N","year":"2022","unstructured":"Nampota-Nkomba N, Nyirenda OM, Khonde L, et al.. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial. Lancet Glob Health. 2022, 10:e1326-35. 10.1016\/S2214-109X(22)00275-3","journal-title":"Lancet Glob Health"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00455-2","article-title":"Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial","volume":"22","author":"Kumar Rai G","year":"2022","unstructured":"Kumar Rai G, Saluja T, Chaudhary S, et al.. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. Lancet Infect Dis. 2022, 22:529-40. 10.1016\/S1473-3099(21)00455-2","journal-title":"Lancet Infect Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2150030","article-title":"Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV\u00ae) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children","volume":"18","author":"Vadrevu KM","year":"2022","unstructured":"Vadrevu KM, Dugyala R, Mahantashetti NS, Khalatkar V, Murthy K, Mogre S, Mitra M. Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV\u00ae) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children. Hum Vaccin Immunother. 2022, 18:2150030. 10.1080\/21645515.2022.2150030","journal-title":"Hum Vaccin Immunother"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.03.089","article-title":"An open-label, comparative, single dose, clinical Phase \u2160 study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults","volume":"39","author":"Choi SK","year":"2021","unstructured":"Choi SK, Baik YO, Kim CW, et al.. An open-label, comparative, single dose, clinical Phase \u2160 study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults. Vaccine. 2021, 39:2620-7. 10.1016\/j.vaccine.2021.03.089","journal-title":"Vaccine"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.073","article-title":"Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV\u00ae) vaccine up to 7\u202fyears following primary vaccination of children","volume":"39","author":"Vadrevu KM","year":"2021","unstructured":"Vadrevu KM, Raju D, Rani S, et al.. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV\u00ae) vaccine up to 7\u202fyears following primary vaccination of children. Vaccine. 2021, 39:6682-90. 10.1016\/j.vaccine.2021.07.073","journal-title":"Vaccine"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of a typhoid conjugate vaccine in Malawian children","volume":"385","author":"Patel PD","year":"2021","unstructured":"Patel PD, Patel P, Liang Y, et al.. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. N Engl J Med. 2021, 385:1104-15. 10.1056\/NEJMoa2035916","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.103","article-title":"Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso","volume":"102","author":"Sirima SB","year":"2021","unstructured":"Sirima SB, Ouedraogo A, Barry N, et al.. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. Int J Infect Dis. 2021, 102:517-23. 10.1016\/j.ijid.2020.10.103","journal-title":"Int J Infect Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.05.061","article-title":"Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial","volume":"108","author":"Sirima SB","year":"2021","unstructured":"Sirima SB, Ouedraogo A, Barry N, et al.. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. Int J Infect Dis. 2021, 108:465-72. 10.1016\/j.ijid.2021.05.061","journal-title":"Int J Infect Dis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial","volume":"9","author":"Shakya M","year":"2021","unstructured":"Shakya M, Voysey M, Theiss-Nyland K, et al.. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health. 2021, 9:e1561-8. 10.1016\/S2214-109X(21)00346-6","journal-title":"Lancet Glob Health"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri F","year":"2021","unstructured":"Qadri F, Khanam F, Liu X, et al.. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet. 2021, 398:675-84. 10.1016\/S0140-6736(21)01124-7","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-020-1890-y","article-title":"Immunogenicity and safety of typhoid conjugate vaccine in healthy Indian subjects: a randomized, active-controlled, comparative clinical trial","volume":"57","author":"Kundu R","year":"2020","unstructured":"Kundu R, Kandulna AK, Nayak U, et al.. Immunogenicity and safety of typhoid conjugate vaccine in healthy Indian subjects: a randomized, active-controlled, comparative clinical trial. Indian Pediatr. 2020, 57:625-30. 10.1007\/s13312-020-1890-y","journal-title":"Indian Pediatr"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007912","article-title":"A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: a novel protein capsular matrix vaccine candidate for the prevention of typhoid fever","volume":"14","author":"Cartee RT","year":"2020","unstructured":"Cartee RT, Thanawastien A, Griffin Iv TJ, Mekalanos JJ, Bart S, Killeen KP. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: a novel protein capsular matrix vaccine candidate for the prevention of typhoid fever. PLoS Negl Trop Dis. 2020, 14:e0007912. 10.1371\/journal.pntd.0007912","journal-title":"PLoS Negl Trop Dis"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.074","article-title":"Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: a preliminary report","volume":"38","author":"Capeding MR","year":"2020","unstructured":"Capeding MR, Alberto E, Sil A, et al.. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: a preliminary report. Vaccine. 2020, 38:4476-83. 10.1016\/j.vaccine.2019.09.074","journal-title":"Vaccine"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-020-02375-4","article-title":"A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11\u2009years: a phase II preliminary report","volume":"20","author":"Medise BE","year":"2020","unstructured":"Medise BE, Soedjatmiko S, Gunardi H, et al.. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11\u2009years: a phase II preliminary report. BMC Pediatr. 2020, 20:480. 10.1186\/s12887-020-02375-4","journal-title":"BMC Pediatr"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.045","article-title":"One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: safety and immunogenicity of Vi-DT typhoid conjugate vaccine","volume":"93","author":"Medise BE","year":"2020","unstructured":"Medise BE, Soedjatmiko S, Gunardi H, et al.. One-month follow up of a randomized clinical trial-phase II study in 6 to &lt;24 months old Indonesian subjects: safety and immunogenicity of Vi-DT typhoid conjugate vaccine. Int J Infect Dis. 2020, 93:102-7. 10.1016\/j.ijid.2020.01.045","journal-title":"Int J Infect Dis"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal","volume":"381","author":"Shakya M","year":"2019","unstructured":"Shakya M, Colin-Jones R, Theiss-Nyland K, et al.. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. N Engl J Med. 2019, 381:2209-18. 10.1056\/NEJMoa1905047","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180238","article-title":"Structural and immunological characterization of E. coli derived recombinant CRM(197) protein used as carrier in conjugate vaccines","volume":"38","author":"Mishra RP","year":"2018","unstructured":"Mishra RP, Yadav RS, Jones C, et al.. Structural and immunological characterization of E. coli derived recombinant CRM(197) protein used as carrier in conjugate vaccines. Biosci Rep. 2018, 38:BSR20180238. 10.1042\/BSR20180238","journal-title":"Biosci Rep"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00387-10","article-title":"Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi","volume":"18","author":"Rondini S","year":"2011","unstructured":"Rondini S, Micoli F, Lanzilao L, Hale C, Saul AJ, Martin LB. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi. Clin Vaccine Immunol. 2011, 18:460-8. 10.1128\/CVI.00387-10","journal-title":"Clin Vaccine Immunol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.072","article-title":"Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use","volume":"28","author":"Shinefield HR","year":"2010","unstructured":"Shinefield HR. Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use. Vaccine. 2010, 28:4335-9. 10.1016\/j.vaccine.2010.04.072","journal-title":"Vaccine"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development, and clinical trials","volume":"9","author":"Pichichero ME","year":"2013","unstructured":"Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013, 9:2505-23. 10.4161\/hv.26109","journal-title":"Hum Vaccin Immunother"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1086048","article-title":"Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and cross reacting material 197 (CRM197) when used as carrier proteins in glycoconjugates","volume":"12","author":"Br\u00f6ker M","year":"2016","unstructured":"Br\u00f6ker M. Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and cross reacting material 197 (CRM197) when used as carrier proteins in glycoconjugates. Hum Vaccin Immunother. 2016, 12:664-7. 10.1080\/21645515.2015.1086048","journal-title":"Hum Vaccin Immunother"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1119","article-title":"The design and analysis of seroefficacy studies for typhoid conjugate vaccines","volume":"68","author":"Liu X","year":"2019","unstructured":"Liu X, Pitzer VE, Pollard AJ, Voysey M. The design and analysis of seroefficacy studies for typhoid conjugate vaccines. Clin Infect Dis. 2019, 68:S183-90. 10.1093\/cid\/ciy1119","journal-title":"Clin Infect Dis"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad021","article-title":"Seroepidemiology for enteric fever: emerging approaches and opportunities","volume":"10","author":"Aiemjoy K","year":"2023","unstructured":"Aiemjoy K, Seidman JC, Charles RC, Andrews JR. Seroepidemiology for enteric fever: emerging approaches and opportunities. Open Forum Infect Dis. 2023, 10:S21-5. 10.1093\/ofid\/ofad021","journal-title":"Open Forum Infect Dis"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.04.014","article-title":"Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh","volume":"41","author":"Khanam F","year":"2023","unstructured":"Khanam F, Babu G, Rahman N, et al.. Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh. Vaccine. 2023, 41:3137-40. 10.1016\/j.vaccine.2023.04.014","journal-title":"Vaccine"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201116","article-title":"Vi-specific serological correlates of protection for typhoid fever","volume":"218","author":"Jin C","year":"2021","unstructured":"Jin C, Hill J, Gunn BM, et al.. Vi-specific serological correlates of protection for typhoid fever. J Exp Med. 2021, 218: e20201116. 10.1084\/jem.20201116","journal-title":"J Exp Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008171","article-title":"Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT)","volume":"14","author":"Lee EY","year":"2020","unstructured":"Lee EY, Park JY, Kim DR, et al.. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT). PLoS Negl Trop Dis. 2020, 14:e0008171. 10.1371\/journal.pntd.0008171","journal-title":"PLoS Negl Trop Dis"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan VK","year":"2015","unstructured":"Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015, 61:393-402. 10.1093\/cid\/civ295","journal-title":"Clin Infect Dis"},{"key":"ref69","unstructured":"Clinical study to assess the immune response and safety of typhoid conjugate vaccine of Cadila Healthcare Limited and compare it to typhoid conjugate vaccine of Bharat Biotech International Limited in healthy human subjects. (2016). Accessed. January 19, 2024: http:\/\/ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=15171&amp;EncHid=&amp;userName=CTRI\/2016\/05\/006975."},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: phase I trial in Healthy Filipino adults and children","volume":"36","author":"Capeding MR","year":"2018","unstructured":"Capeding MR, Teshome S, Saluja T, et al.. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: phase I trial in Healthy Filipino adults and children. Vaccine. 2018, 36:3794-801. 10.1016\/j.vaccine.2018.05.038","journal-title":"Vaccine"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.11.6586-6588.2004","article-title":"Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children","volume":"72","author":"Canh DG","year":"2004","unstructured":"Canh DG, Lin FY, Thiem VD, et al.. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun. 2004, 72:6586-8. 10.1128\/IAI.72.11.6586-6588.2004","journal-title":"Infect Immun"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta ZA","year":"2014","unstructured":"Bhutta ZA, Capeding MR, Bavdekar A, et al.. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis. 2014, 14:119-29. 10.1016\/S1473-3099(13)70241-X","journal-title":"Lancet Infect Dis"},{"key":"ref73","article-title":"Safety and Immunogenicity of salmonella Typhi Vi conjugate vaccine (PedaTyph\u2122) in children upto five years","volume":"3","author":"Chinnasami B","year":"2013","unstructured":"Chinnasami B, Mangayarkarasi V, Prema A, Sadasivam K, Davis MJ. Safety and Immunogenicity of salmonella Typhi Vi conjugate vaccine (PedaTyph\u2122) in children upto five years. Int J Sci Res. 2013, 3:1-5.","journal-title":"Int J Sci Res"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1117715","article-title":"Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph\u2122) in Indian children: school based cluster randomized study","volume":"12","author":"Mitra M","year":"2016","unstructured":"Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, Basu S. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph\u2122) in Indian children: school based cluster randomized study. Hum Vaccin Immunother. 2016, 12:939-45. 10.1080\/21645515.2015.1117715","journal-title":"Hum Vaccin Immunother"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa597","article-title":"Decision making and implementation of the first public sector introduction of typhoid conjugate vaccine-Navi Mumbai, India, 2018","volume":"71","author":"Date K","year":"2020","unstructured":"Date K, Shimpi R, Luby S, et al.. Decision making and implementation of the first public sector introduction of typhoid conjugate vaccine-Navi Mumbai, India, 2018. Clin Infect Dis. 2020, 71:S172-8. 10.1093\/cid\/ciaa597","journal-title":"Clin Infect Dis"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001261.pub4","article-title":"Vaccines for preventing typhoid fever","volume":"5","author":"Milligan R","year":"2018","unstructured":"Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2018, 5:CD001261. 10.1002\/14651858.CD001261.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-019-1566-7","article-title":"Opportunities for typhoid vaccination in India","volume":"56","author":"Srinivasan M","year":"2019","unstructured":"Srinivasan M, Sindhu KN, John J, Kang G. Opportunities for typhoid vaccination in India. Indian Pediatr. 2019, 56:453-8. 10.1007\/s13312-019-1566-7","journal-title":"Indian Pediatr"},{"key":"ref78","unstructured":"Global Market Study Typhoid Vaccines. (2020). Accessed. January 19, 2024: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/mi4a\/typhoid_vaccines-market_study_public_summary-november...."},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy878","article-title":"Introduction of typhoid conjugate vaccines in Africa and Asia","volume":"68","author":"Neuzil KM","year":"2019","unstructured":"Neuzil KM, Pollard AJ, Marfin AA. Introduction of typhoid conjugate vaccines in Africa and Asia. Clin Infect Dis. 2019, 68:S27-30. 10.1093\/cid\/ciy878","journal-title":"Clin Infect Dis"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.05.001","article-title":"Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings","volume":"35","author":"Antill\u00f3n M","year":"2017","unstructured":"Antill\u00f3n M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017, 35:3506-14. 10.1016\/j.vaccine.2017.05.001","journal-title":"Vaccine"},{"key":"ref81","article-title":"Emergence of Salmonella typhi Vi antigen-negative strains in an epidemic of multidrug-resistant typhoid fever cases in Calcutta, India","volume":"13","author":"Saha MR","year":"2000","unstructured":"Saha MR, Ramamurthy T, Dutta P, Mitra U. Emergence of Salmonella typhi Vi antigen-negative strains in an epidemic of multidrug-resistant typhoid fever cases in Calcutta, India. Natl Med J India. 2000, 13:164.","journal-title":"Natl Med J India"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/211374-typhoid-conjugate-vaccine-a-boon-for-endemic-regions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T11:30:02Z","timestamp":1710847802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/211374-typhoid-conjugate-vaccine-a-boon-for-endemic-regions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":81,"URL":"https:\/\/doi.org\/10.7759\/cureus.56454","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}